Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Doubles Down On Antitrust, M&A With Another Partner Hire (Reuters)

Related Content

European Commission’s First-Ever Abuse of Dominance Probe for Shelving of a Novel Pipeline Therapy

Antitrust & Competition Technology Quarterly Update Q3 2023

Antitrust & Competition Life Sciences Quarterly Update Q3 2023

Antitrust & Competition Technology Quarterly Update Q2 2023

Antitrust & Competition Life Sciences Quarterly Update Q2 2023

Antitrust & Competition Healthcare Quarterly Update Q2 2023

Antitrust & Competition Technology Quarterly Update Q1 2023

Antitrust & Competition Healthcare Quarterly Update Q1 2023

Informa Connect Antitrust West Coast 2024 Conference

Goodwin CLE Days 2024

Renesas to Acquire Transphorm in $339 Million Transaction

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Harpoon Therapeutics To Be Acquired by Merck for $680 Million

Stirling Square, TA and Macquarie Capital, through Giant BidCo, announce a recommended public cash offer of SEK 46 to the shareholders of Byggfakta

Goodwin Named an Elite Firm for Antitrust Law by GCR 100 2024

Cigna-Humana Deal Would Face Intense Anti-Trust Scrutiny (Axios)

Technology

Life Sciences

Private Equity

Medtech

Antitrust & Competition

Mergers & Acquisitions

Complex Litigation & Dispute Resolution

Antitrust Services for Life Sciences Companies

Litigation